Abstract

Gastrointestinal (GI) defects, including gastroesophageal reflux, constipation and delayed gastric emptying, are common in patients with spinal muscular atrophy (SMA). Similar GI dysmotility has been identified in mouse models with survival of motor neuron (SMN) protein deficiency. We previously described vascular defects in skeletal muscle and spinal cord of SMA mice and we hypothesized that similar defects could be involved in the GI pathology observed in these mice. We therefore investigated the gross anatomical structure, enteric vasculature and neurons in the small intestine in a severe mouse model of SMA. We also assessed the therapeutic response of GI histopathology to systemic administration of morpholino antisense oligonucleotide (AON) designed to increase SMN protein expression. Significant anatomical and histopathological abnormalities, with striking reduction of vascular density, overabundance of enteric neurons and increased macrophage infiltration, were detected in the small intestine in SMA mice. After systemic AON treatment in neonatal mice, all the abnormalities observed were significantly restored to near-normal levels. We conclude that the observed GI histopathological phenotypes and functional defects observed in these SMA mice are strongly linked to SMN deficiency which can be rescued by systemic administration of AON. This study on the histopathological changes in the gastrointestinal system in severe SMA mice provides further indication of the complex role that SMN plays in multiple tissues and suggests that at least in SMA mice restoration of SMN production in peripheral tissues is essential for optimal outcome.

Highlights

  • Spinal muscular atrophy (SMA) is one of the most common genetic diseases in childhood and the leading genetic cause of infant mortality [1]

  • SMA is caused by functional loss of the survival of motor neuron (SMN) protein resulting from homozygous genomic deletion or mutations of the survival of motor neuron 1 (SMN1) gene

  • The antisense oligonucleotide (AON) used in this study is a 25-mer morpholino antisense oligomer, PMO25, which is designed to augment the splicing of exon7 in SMN2 gene by targeting the intronic splicing silencer N1 element (ISS-N1) element in intron 7

Read more

Summary

Introduction

Spinal muscular atrophy (SMA) is one of the most common genetic diseases in childhood and the leading genetic cause of infant mortality [1]. It is characterized by progressive degeneration of spinal motor neurons leading to proximal skeletal muscle atrophy and paralysis. SMA is caused by functional loss of the survival of motor neuron (SMN) protein resulting from homozygous genomic deletion or mutations of the survival of motor neuron 1 (SMN1) gene. A single nucleotide (C to T) variation at position 6 in exon 7 affects the efficiency of splicing of this exon in the SMN2 gene, leading to approximately 90% of transcripts lacking exon 7 [2,3]. The copy numbers of SMN2 gene, which vary in the general population, are important in modulation of disease severity [4,5,6]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.